Company:  MARINUS PHARMACEUTICALS I ... (MRNS)
Form Type:  SC 13G/A
Filing Date:  2/14/2020 
CIK:  0001267813 
Address:  5 RADNOR CORPORATE CENTER SUITE 500
100 MATSONFORD RD
 
City, State, Zip:  RADNOR, Pennsylvania 19087 
Telephone:  484-801-4670 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.54  
Change: 
-0.13 (-4.87%)  
Trade Time: 
Jul 02  
Market Cap: 
$260.94M
Trade MRNS now with 

© 2020  
Description of Business
We are a clinical stage pharmaceutical company focused on developing and commercializing innovative therapeutics to treat patients suffering from rare seizure disorders. Our clinical stage product candidate, ganaxolone, is a positive allosteric modulator of GABAA that is being developed in formulations for two different routes of administration: intravenous (IV) and oral. Ganaxolone is a synthetic analog of allopregnanolone, an endogenous neurosteroid. The different formulations are intended to maximize potential therapeutic applications of ganaxolone for adult and pediatric patient populations, in both acute and chronic care, and for both in­patient and self­administered settings. Ganaxolone acts at both synaptic and extrasynaptic GABAA receptors and exhibits anti­seizure, antidepressant and anxiolytic properties.
Register and access this filing in:     
  FORM SC 13G/A